Sophia Haywood

Refining prognosis in advanced renal cell carcinoma: international real-world validation of the Meet-URO score in first-line immunotherapy combinations

Sara Elena Rebuzzi, Aruni Ghose, S. Rudman, Balaji Venugopal et autres

BACKGROUND: Effective risk stratification is essential for guiding treatment decisions in patients with metastatic renal cell carcinoma (mRCC). The Meet-URO score is a novel prognostic model that integrates the International Metastatic RCC Database Consortium (IMDC) criteria with neutrophil-to-lymphocyte ratio (NLR) and the …

it, gb, cz, tr, hk, us (code pays fourni par la source)

2645P Prognostic performance of the meet-URO score in an international real-world cohort of metastatic renal cell carcinoma (mRCC) patients receiving first-line immune-combinations

Sara Elena Rebuzzi, Aruni Ghose, N Brown, Sophia Haywood et autres

it, gb, cz (code pays fourni par la source)

IUC24394-87 Meet-URO score update in metastatic renal cell carcinoma receiving first-line immune-combinations

Pasquale Rescigno, Aruni Ghose, Nicholas F. Brown, Lijo James et autres

Abstract Background Risk stratification is fundamental in guiding treatment decisions for mRCC patients. The Meet-URO score is a novel prognostic model (IMDC score + NLR + Bone metastases, PMID 36493602) developed in the immunotherapy era. This innovative score enhanced the prognostic discrimination …

gb, cz, it (code pays fourni par la source)

Ureteric calculi and abdominal distension

Sophia Haywood, Shaheen Somani, Glenn Miller, Christopher Wilkinson et autres

gb (code pays fourni par la source)

Quantitative and Spatial Analysis of CD8+/PD-1 Tumor-Infiltrating Lymphocytes as a Predictive Biomarker for Clinical Response of Melanoma In-Transit Metastases to Topical Immunotherapy

Sophia Haywood, J. Garioch, Arjun Ramaiya, Marc Moncrieff

BACKGROUND: Melanoma in-transit metastases (ITMs) are a challenge to treat and associated with systemic disease and poor prognosis. Topical diphencyprone (DPCP), a potent contact sensitizer, is an established treatment for melanoma ITMs. This exploratory study investigated the utility of BRAF mutation status, …

gb (code pays fourni par la source)